ZOLOFT WARNING LETTER RELEASE COINCIDES WITH PFIZER ANALYST MEETING; SECOND WARNING LETTER TO PFIZER TO RECEIVE NATIONAL MEDIA ATTENTION THIS YEAR
Executive Summary
FDA's public release of its Aug. 1 warning letter to Pfizer on promotions of Zoloft coincided with the company's regularly scheduled quarterly briefing for the financial community and quickly overshadowed the company's prepared update on its business.